CSPC’s JSKN003 Gains Breakthrough Therapy Status for Colorectal Cancer

CSPC Pharmaceutical Group ( (HK:1093) ) just unveiled an update.

CSPC Pharmaceutical Group announced that its drug JSKN003 has received another Breakthrough Therapy Designation from China’s National Medical Products Administration for treating HER2-positive advanced colorectal cancer. This designation highlights the drug’s promising efficacy and safety profile, potentially enhancing the company’s position in the oncology market and addressing significant unmet clinical needs in cancer treatment.

The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group is a Hong Kong-based company involved in the pharmaceutical industry, focusing on the development and production of innovative drugs. The company is engaged in creating treatments for various diseases, with a particular emphasis on cancer therapies.

YTD Price Performance: 88.51%

Average Trading Volume: 169,438,738

Technical Sentiment Signal: Buy

Current Market Cap: HK$100.8B

See more insights into 1093 stock on TipRanks’ Stock Analysis page.